Dr. Reddy's Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market

Hyderabad, India, May 15, 2019                                                                                                             

Hyderabad, India and Princeton, NJ, USA. May 15, 2019— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Daptomycin for Injection, 500mg/vial single-dose vial, a therapeutic equivalent generic version of Cubicin® for Injection, approved by the U.S. Food and Drug Administration (USFDA). 

The Cubicin® for Injection (daptomycin for injection) brand and generic had U.S. sales of approximately $640.8 million MAT for the most recent twelve months ending in March 2019 according to IQVIA Health*.

Dr. Reddy’s Daptomycin for Injection is available in single-dose 15 ml vials containing 500 mg of daptomycin.

Cubicin is a trademark of Merck Sharp & Dohme Corp.

*IQIA Retail and Non-Retail MAT March  2019

RDY-0519-246